ProTrans

Apr 27, 2023

NextCell Pharma AB Thu, Apr 27, 2023 07:30 CET NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 2 for the period December 1, 2022 – February 28, 2023 The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report . NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year. Operating income amounted to 2,734 (1,840) TSEK, of which Cellaviva counted for 2,106 (1,279) TSEK. First half year (2022-09-01 until 2023-02-28) Operating income amounted to 5,747 (3,187) TSEK of which Cellaviva counted for 4,244 (2,616) TSEK. Earnings per share* amounted to -0.59 (-0.49) SEK. *Earnings per share: Profit for the period divided by average number of shares. Average number of shares for the second quarter 2022/2023: 34,379,523 (34,379,523)  shares. Number of shares in NextCell as of February 28, 2022: 34,379,523 (34,379,523) shares. **Solidity: Own capital's share of the sheet total. Significant events in the second quarter NextCell announced at the end of March that the first two adolescents in the older age cohort (12-21 years) had undergone treatment in the phase II part of the childhood diabetes study. The company announced in mid-January that it had received positive comments and recommendations on the draft pediatric plan (PIP) previously submitted to the European Medicines Agency's pediatric unit (PDCO). NextCell announced at the end of January that it is expanding the ProTrans study in COVID-19 to the treatment of severe pneumonia caused by flu, RS and HMP virus. Significant events after the reporting period NextCell announced at the end of March that the results of the clinical phase I/II study in type 1 diabetes had been accepted for publication in the peer-reviewed journal Diabetologia, the official journal of the European Association for the Study of Diabetes The company announced late April that the FDA has approved a product of multiplied stem cells from umbilical cord blood. It is a breakthrough that could lead to increased interest in saving stem cells for private use, where Cellaviva is the market leader in Scandinavia. This disclosure contains information that NextCell Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 27-04-2023 07:30 CET. For more information about NextCell Pharma, please contact Mathias Svahn, CEO About NextCell Pharma AB NextCell is a cell therapy company in clinical phase II. The company has developed a proprietary and patented platform technology to produce mesenchymal stromal cells adapted for allogeneic treatment of various autoimmune and immunological diseases. The drug candidate ProTrans is now being tested for the treatment of type-1 diabetes as well as respiratory complications caused by Sars-CoV-2 infection. The focus is to take ProTrans to market approval for type-1 diabetes via a phase III study. ProTrans is evaluated in two clinical COVID-19 studies, in Sweden and Canada. NextCell is working on completing its own GMP facility for the manufacture of ProTrans. The GMP facility is expected to be ready for manufacturing smaller quantities of ProTrans in 2023. NextCell also owns 8.5% of FamicordTX, a start-up company in CAR-T and oncology, and 100% of Cellaviva, Scandinavia's largest stem cell bank for family savings of stem cells from umbilical cord blood and umbilical cord tissue with permission from the Swedish Health and Social Care Inspectorate (IVO).